Search Results

Impulse Dynamics plc is proud to announce that it raised $136 million in financing to accelerate investment in global commercialization, technology, product innovation, and further development of clinical evidence.

NeuShen Therapeutics (the “Company”) today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of NS-136, a novel selective M4 receptor positive allosteric modulator (M4 PAM) designed for the treatment of schizophrenia and other conditions associated with psychosis.

The American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today’s science to end the burden of lung disease tomorrow.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced financing facilities securing gross proceeds of approximately $136 million, at current exchange rates.

The Insight Partners published latest research report on “Biosimilars Market Growth Report, Size, Share, Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Indication, Drug Class, Route of Administration, and End User”, the global market is expected to grow from USD 18,435.89 million in 2021 to USD 136,069.53 million by 2028; it is estimated to record a CAGR of 34.8% from 2022 to 2028.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity.